Preventive effect of alprostadil on contrast-induced nephropathy in patients undergoing coronary intervention
10.3760/cma.j.issn.1673-4904.2013.04.012
- VernacularTitle:前列地尔对冠状动脉介入诊疗术患者造影剂肾病的预防作用
- Author:
Dongchi ZHOU
;
Ming LU
;
Zhiqiang LI
- Publication Type:Journal Article
- Keywords:
Alprostadil;
Contrast-induced nephropathy;
Prevention
- From:
Chinese Journal of Postgraduates of Medicine
2013;(4):34-36
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the preventive effect of alprostadil on contrast-induced nephropathy (CIN) in patients undergoing coronary intervention.Methods Two hundred and fifteen patients undergoing coronary intervention were divided into treatment group (112 cases) and control group (103 cases) by random digits table method.Patients in treatment group were treated routinely with addition of alprostadil (10 μ g intravenous injection every 12 h once for 7-10 days,given before surgery).Patients in control group were given routine therapy only.Complications of the two groups and CIN occurrence were observed.Results The occurrence rate of CIN in treatment group was lower than that in control group[7.1％ (8/112) vs.18.4％ (19/103),P ＜ 0.05].The occurrence rate of CIN in patients with renal insufficiency was higher than that in patients with normal renal function [51.6％ (16/31) vs.6.0％ (11/184),P ＜ 0.01].The occurrence rate of CIN in patients with diabetes was higher than that in patients without diabetes [22.1％(15/68) vs.8.2％ (12/147),P ＜ 0.01].Conclusions Alprostadil in coronary intervention before treatment can obviously reduce the incidence of CIN.CIN is more likely to occur in patients with renal insufficiency or with diabetes.
